On the 27th, Samsung C&T's stock is strong by over 3%. The expectation of benefits from the spin-off of its subsidiary, Samsung Biologics, along with its entries into small modular reactors (SMR) and the aerospace rear industry is interpreted as improving buying sentiment.
As of 9:16 a.m. on the 27th, Samsung C&T shares are trading at 157,650 won, up 5,550 won (3.65%) from the previous trading day on the Korea Securities Market.
Park Jong-ryeol, a researcher at Heungkuk Securities, analyzed that 'beneath the rise in Samsung C&T's stock lies the benefit of revitalizing the capital market.'
The researcher evaluated that several factors such as the spin-off of Samsung Biologics, entry into the aerospace rear industry, growth expectations in the SMR field, and the potential for expanded shareholder returns and stock re-evaluation following changes to corporate law are working together to drive the stock price.